I joined the supercomputer manufacturer Cray Japan Inc. and later merged with SGI Japan Inc. Following roles as Graphics Business Division Manager and Executive Officer, Strategy Business Promotion Division Director, I established Segway Japan Inc. through a Management Buyout (MBO) in 2008 and became the Representative Director and President (currently Chairman). As part of our new business initiatives, I proposed the robot business and implemented its elements across various corporate entities.
In the near future, aiming to contribute to universal human themes such as health, prevention, and pre-illness in a coexistent society with robots, I am actively operating PST Inc. for the research, development, and commercialization of the crucial technology ”Vocal Biomarker." I am taking on the challenge of launching and expanding this initiative from Japan to the global stage.

Former investment specialist in Life Sciences/Healthcare at British Embassy in Japan/ Department for International Trade (DIT), formerly UK Trade and Investment. Graduated from Department of Biomedical Engineering, University of Southern California, Graduated school of Biomedical Engineering, University of Southern California, Graduate School of Applied Quantum Physics and Nuclear Engineering, Kyushu University. Studied abroad in Silicon Valley, spent his youth in California, and returned home. As a researcher in Value Economics Engineering and Wellness Economics (author: "Value" that becomes money and "value" that does not - THE Introduction to Value Economics Engineering), he specializes in applying behavioral economics and financial engineering to business and quality of life creation. He has over 20 years of experience in management and global finance, and his hobby is entertaining people as a sommelier.

Ph.D. in Engineering. Visiting Professor at Global Innovation Center at Kyushu University. Invited Visiting Professor at the University of Information Technology.

Hiroyuki has been involved in investment banking (incl. cross-border M&A advisory services) and international development finance and investment as well as corporate management practice for about 30 years. He has focused on planning and executing strategic business development and capital policy for enterprises in a broad range of industries.
 
He was a founding member and partner of the GCA Corporation, HQs in Tokyo, a first, leading independent, international investment banking advisory firm, listed on Tokyo Stock Exchange 1st Section since 2007, and merged with Houlihan Lokey, Inc. in 2021.
 
He spent about many years of his career at the World Bank Group in Washington DC, as an operations officer and investment officer, where he focused on project finance for infrastructure projects and privatization advisory services. The Cambodia water supply development project, that he was engaged in as a project officer drew much attention as it was the first full-scale post-civil war World Bank-financed project in the country. The project, came to be known as the “Miracle of Phnom Penh”, is still recognized as a success model for development of the water supply and sanitation sector in developing countries.
 
He has also served as a director (mainly in charge of business development), outside director, and audit committee member of multiple listed companies.

With a distinguished career spanning over 25 years, Hiroto MOTOHATA held executive positions at Goldman Sachs, Merrill Lynch Japan Securities Co., Ltd., Credit Suisse Securities Ltd., and Mizuho Securities Co., Ltd. He demonstrated remarkable accomplishments in both investment banking and asset management. Subsequently, he embarked on an innovative and pioneering initiative, the first of its kind in Japan, to realize the "Family Office Concept," founding Brookfield Capital. In this endeavor, he achieved a capital and business partnership between Brookfield Capital and the SBI Group, assuming various directorial roles within multiple SBI Group companies, including that of Executive Vice President at SBI Securities Co., Ltd.
 
Also, he has taken a special interest in addressing the challenges of enhancing corporate value and succession planning for small and medium-sized enterprises and he established Vision Craft Inc., where he currently serves as the Chief Executive Officer. He plays a pivotal role as an executive advisor for numerous companies, actively contributing to the resolution of these issues. Demonstrating a strong commitment to fostering entrepreneurial ventures, he has engaged in hands-on support as an angel investor for more than ten companies.
 
Chief Executive Officer, Vision Craft Inc.

Tsutomu IIJIMA specializes in branding, notably in cutting-edge science and technology, regional branding, and social branding for NPOs/NGOs. With experience as a development advisor across diverse sectors including home appliance industry, automobile industry, and the general construction industry, he provides consulting on human resource and capability development for governments and companies. He also engages in coordination for the social implementation of science and technology in collaboration with universities and research institutins.
 
Founder and Representative, CO-WORKS
Board Member, Innovation Design Lab, a General Incorporated Association
Special Member, Health Care & Service Effectiveness Measurement Consortium, National Institute of Advanced Industrial Science and Technology (AIST)
Advisor, STEAM Association, a General Incorporated Association
Counselor, Hot Air Balloon Operation Organization, a Nonprofit Organization
Engages in human resource development within local municipalities and Japanese corporations
Career advancement trainer, Doctoral Program, Faculty of Science, University of Tokyo
Coordinator for the societal application of science and technology at various Japanese universities and research entities
Planner for S-BOOSTER, Cabinet Office's Space Development Strategy Promotion Office. Acts as a mentor in the same capacity

Dr. Chung graduated from University of Tokyo School of Medicine. During the course of graduate study, he went to Massachusetts General Hospital, and was appointed Instructor in Medicine, Harvard Medical School, and then Assistant Professor of Medicine. He came back to his alma mater to work at Graduate Schools of Medicine and Engineering. In 2007, he became Professor, Graduate School of Engineering, and in 2016, Professor, Graduate School of Medicine as well. In 2019, he also starts serving as Dean and Professor, at School of Health Innovation, Kanagawa University of Human Services, and in 2021, as Executive Board Member and Vice President as well. He specializes in skeletal biology/regenerative medicine and biomaterials science. He also promotes industry-academia cooperation projects to measure and visualize health status of each individual for health personalization and behavior change. In Kanagawa University of Human Services, he attempts to systematize and academicize ME-BYO concept for social implementation. He also studies the role of morality in Innovation management. He is a board member of the Japanese Society for Regenerative Medicine.
 
Yuichi Tei/Ung-il Chung, M.D., Ph.D.
Professor, Department of Bioengineering, Graduate Schools of Engineering and Medicine, The University of Tokyo
Executive Board Member, Vice President and Dean, School of Health Innovation, Kanagawa University of Human Services

Koji NAKAO joined Terumo Corporation (one of the major Medical Device companies in Japan) . In addition to engaging in a wide range of responsibilities including Sales & Marketing, Corporate Planning and M&A, he also lived overseas for 15 years, mainly in the United States and Europe, and contributed to the growth of the company's global business. He served as the company's Representative Director and Chairman of the board from 2011 to 2016, and was also dedicated in activities for the advancement of the medical device industry as Chairman of the Japan Federation of Medical Devices Associations until 2017. He introduced Biodesign Program (MedTech innovation) to Tohoku University, University of Tokyo and Osaka University in 2015. The program continues over eight years and has produced many fellows and results of innovation. While mentoring the fellows, he serves advisory jobs and the outside director positions of Medtech and startup companies.

Ph.D.
Special Advisor (Founder), Japan Biodesign Academic Society

Ryosuke DOKAN started his career at a major pharmaceutical company in Japan. He played a key role in launching the company’s global businesses while driving profitability improvement and enhancing business infrastructure in Japan. Also, he has extensive experience of advancing the growth of the pharmaceutical and medical device industry, as well as in elevating healthcare standards in developing countries during his tenure at the Ministry of Health, Labour and Welfare. Over the course of his more than 20-year career, he has devoted roughly 50% of his efforts to launching new business, with the remaining 50% dedicated to improving profitability through initiatives like M&A, PMI, restructuring and partnerships etc. He joined PST in January 2023, and has been leading and driving the company's overall strategy.
 
MBA, CMA, CEO of PST Medical Inc.

As a medical professional, he was involved in acute care for more than 10 years in various disease areas mainly at university hospitals, and at graduate school, he majored in global health and was involved in international joint research and international cooperation in medicine.

He then engaged in corporate development, and as manager of overseas medical business development at a Japanese corporation, he was mainly engaged in skill development projects for medical experts in China and consultation projects for improving local medical systems, and was responsible for a wide range of responsibilities including legal affairs and intellectual property.

Since joining PST Inc., he has been playing a cross-functional role in many projects, aiming to establish a next-generation healthcare system that combines medical care, voice AI, and IT based on his extensive medical career, data science, and IT development background.

PST Inc. Vice President, Senior Director of Innovation Strategy Division.
UIX Inc. CEO,
PhD,
Physical therapist

He was awarded a Ph.D. in Engineering in 2009 for his university research on super-resolution and function-based description of speech and images, and he has been engaged in research on speech pathology analysis technology for over 20 years. His achievements, from basic research to application, include more than 20 original papers and reviews, more than 100 academic papers, and more than 20 patent applications. He has been involved in creating and analyzing speech pathology analysis algorithms using speech properties and machine learning for various diseases since the dawn of PST. 

Yoshiyuki SUGAWARA started his career at a major pharmaceutical company in Japan. He contributed as a sales representative to satisfy the needs of the medical field. Later, as an officer of the company's labor union, he dedicated to the development of the company and the happiness of its employees. During his tenure as Central Executive Committee Chairman, he played a central role in introducing the 65-year-old retirement system, the first case of a company listed on the first section of the Tokyo Stock Exchange. After returning to the company, he was assigned to the domestic pharmaceutical business reorganization project. Also, he was in charge of business strategy planning, promoting corporate philosophy-based management, implementing knowledge creation theory to realize the philosophy, and creating new business models, etc. He joined PST in July 2023, and has been leading Sales & Marketing Strategy Division and Human Resources & Labor function.

Pharmacist, Director of Business Strategy Division, PST Medical Inc.

He started his career as a software development engineer and contributed to the design, development, and project management of medical device software such as in vitro diagnostic(IVD) and sphygmomanometer, etc., home healthcare, and telemedicine systems for about 20 years. Then he worked in regulatory affairs and quality assurance for about 20 years, maintaining ISO 13485 (quality management system for medical devices) certification for 7 years, applying for 8 business licenses for Medical Device Marketing Authorization Holder, etc., and applying for regulatory affairs for 11 IVD products and 7 medical devices. Involved in medical device program development and clinical trials based on IEC 62304 (medical device software life cycle process) as a regulatory affairs officer. He has been in his current position since April 2023. 

He had developed medical equipment at diversified manufacturer centered on chemistry for 20 years.
He designed embedded software and managed products through all life cycle " Product Planning, Design, Going to Production, Meeting Medical Regulation, Post Market Support" at the same time.
He worked that medical software meet standards for medical regulation at diagnostic drug manufacturer. "Building Quality Management System, Risk Management System, etc."
After that, He joined PST at Aug.2023. He led development medical software with making use of his medical experience.

XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX、XXXXXXXXXXXXXXXXXXXXXXXXXXXX。XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX。
XXXXXXXXXXXXXXXXXXXXXX、XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX。

XXXXXXXXXXXXXXXXXXXXXXXXXXXXXX、XXXXXXXXXXXXXXXXXXXXXXXXXXXX。XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX。
XXXXXXXXXXXXXXXXXXXXXX、XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX。